Figure 19

Umbelliferone β-D-galactopyranoside (UFG) effect on liver in different groups of rats: (A) Normal control: Normal control group did not produce any changes in histopathology (B) Diabetic control: Diabetic control group rat shown enlarged of micro droplet of fat (yellow arrow) (C) UFG I (10 mg/kg): Treatment with UFG dose (10 mg/kg) shown some part having micro droplet of fat deposition (yellow arrow). (D) UFG II (20 mg/kg): Treatment with different dose UFG (20 mg/kg) shown few particle of micro droplet of fat in liver histopathology (yellow arrow). (E) UFG III (40 mg/kg): Histopathology of UFG (40 mg/kg) drug not showing any fat deposition and other assortments. (F) Glibenclamide (10 mg/kg): Standard drug treated group shown histopathology similar to the normal control groups. The samples were obtained from the same liver anatomical regions. For each group, 6 rats were examined and 80 pictures were taken. The above picture for each group was chosen randomly from the 80 pictures in this group. Original magnification, 10 × .